Literature DB >> 28369752

Vascular inflammation and low-density lipoproteins: is cholesterol the link? A lesson from the clinical trials.

Alberico Luigi Catapano1,2, Angela Pirillo3, Giuseppe Danilo Norata1,4.   

Abstract

For long time, the role of LDL and inflammation in the pathogenesis of atherosclerosis have been studied independently from each other and only more recently a common platform has been suggested. Accumulation of excess cholesterol due to the presence of increased circulating LDL promotes endothelium dysfunction and activation, which is associated with increased production of pro-inflammatory cytokines, overexpression of adhesion molecules, chemokines and C-reactive protein (CRP), increased generation of reactive oxygen species and reduction of nitric oxide levels and bioavailability. All these processes favour the progressive infiltration of inflammatory cells within the arterial wall where cholesterol accumulates, both extracellularly and intracellularly, and promotes vascular inflammation. According to this, lipid-lowering therapies should improve inflammation and, indeed, statins decrease circulating inflammatory markers such as CRP and improve endothelial function and plaque burden. Pleiotropic activities have been proposed to explain this effect. However, mendelian randomization studies ruled out a direct role for CRP on coronary artery disease and studies with other lipid lowering drugs, such as ezetimibe showed that the beneficial effect of LDL-cholesterol-lowering therapies on systemic inflammatory status, as monitored by changes in CRP plasma levels, could be achieved, independently of the mechanism of action, only in patients presenting with baseline inflamed conditions. These observations strengthen the direct link between cholesterol and inflammation and indicate that decreasing LDL levels is one of the key goals for improving cardiovascular outcome. LINKED ARTICLES: This article is part of a themed section on Targeting Inflammation to Reduce Cardiovascular Disease Risk. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v174.22/issuetoc and http://onlinelibrary.wiley.com/doi/10.1111/bcp.v82.4/issuetoc.
© 2017 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28369752      PMCID: PMC5659993          DOI: 10.1111/bph.13805

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  127 in total

Review 1.  Inflammation and cardiovascular disease: role of the interleukin-1 receptor antagonist.

Authors:  William F Fearon; Douglas T Fearon
Journal:  Circulation       Date:  2008-05-20       Impact factor: 29.690

2.  Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels.

Authors:  I Jialal; D Stein; D Balis; S M Grundy; B Adams-Huet; S Devaraj
Journal:  Circulation       Date:  2001-04-17       Impact factor: 29.690

Review 3.  Effects of statins on coronary and peripheral endothelial function in humans: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Martin K Reriani; Shannon M Dunlay; Bhanu Gupta; Colin P West; Charanjit S Rihal; Lilach O Lerman; Amir Lerman
Journal:  Eur J Cardiovasc Prev Rehabil       Date:  2011-03-04

Review 4.  Effect of high-dose statin versus low-dose statin plus ezetimibe on endothelial function: a meta-analysis of randomized trials.

Authors:  Yicong Ye; Xiliang Zhao; Guangyao Zhai; Lilin Guo; Zhuang Tian; Shuyang Zhang
Journal:  J Cardiovasc Pharmacol Ther       Date:  2012-06-18       Impact factor: 2.457

5.  Inflammation, statin therapy, and risk of stroke after an acute coronary syndrome in the MIRACL study.

Authors:  Scott Kinlay; Gregory G Schwartz; Anders G Olsson; Nader Rifai; Michael Szarek; David D Waters; Peter Libby; Peter Ganz
Journal:  Arterioscler Thromb Vasc Biol       Date:  2007-11-08       Impact factor: 8.311

Review 6.  Effect of interleukin 1β inhibition in cardiovascular disease.

Authors:  Arman Qamar; Daniel J Rader
Journal:  Curr Opin Lipidol       Date:  2012-12       Impact factor: 4.776

Review 7.  Lipid profile changes in patients with chronic inflammatory arthritis treated with biologic agents and tofacitinib in randomized clinical trials: a systematic review and meta-analysis.

Authors:  Alejandro Souto; Eva Salgado; José Ramón Maneiro; Antonio Mera; Loreto Carmona; Juan J Gómez-Reino
Journal:  Arthritis Rheumatol       Date:  2015-01       Impact factor: 10.995

8.  C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20,536 patients in the Heart Protection Study.

Authors: 
Journal:  Lancet       Date:  2011-01-27       Impact factor: 79.321

9.  Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data.

Authors:  Frances Wensley; Pei Gao; Stephen Burgess; Stephen Kaptoge; Emanuele Di Angelantonio; Tina Shah; James C Engert; Robert Clarke; George Davey-Smith; Børge G Nordestgaard; Danish Saleheen; Nilesh J Samani; Manjinder Sandhu; Sonia Anand; Mark B Pepys; Liam Smeeth; John Whittaker; Juan Pablo Casas; Simon G Thompson; Aroon D Hingorani; John Danesh
Journal:  BMJ       Date:  2011-02-15

10.  Changes in mipomersen dosing regimen provide similar exposure with improved tolerability in randomized placebo-controlled study of healthy volunteers.

Authors:  Joann D Flaim; John S Grundy; Brenda F Baker; Mary P McGowan; John J P Kastelein
Journal:  J Am Heart Assoc       Date:  2014-03-13       Impact factor: 5.501

View more
  35 in total

Review 1.  Genetics, Dyslipidemia, and Cardiovascular Disease: New Insights.

Authors:  Ricardo Stein; Filipe Ferrari; Fernando Scolari
Journal:  Curr Cardiol Rep       Date:  2019-06-21       Impact factor: 2.931

Review 2.  Identifying the anti-inflammatory response to lipid lowering therapy: a position paper from the working group on atherosclerosis and vascular biology of the European Society of Cardiology.

Authors:  José Tuñón; Lina Badimón; Marie-Luce Bochaton-Piallat; Bertrand Cariou; Mat J Daemen; Jesus Egido; Paul C Evans; Imo E Hoefer; Daniel F J Ketelhuth; Esther Lutgens; Christian M Matter; Claudia Monaco; Sabine Steffens; Erik Stroes; Cécile Vindis; Christian Weber; Magnus Bäck
Journal:  Cardiovasc Res       Date:  2019-01-01       Impact factor: 10.787

3.  Inflammation and atherosclerosis: fulfilling Koch's postulates.

Authors:  Ishwarlal Jialal; Naval K Vikram
Journal:  Ther Adv Cardiovasc Dis       Date:  2017-11-30

Review 4.  The Interplay of Lipids, Lipoproteins, and Immunity in Atherosclerosis.

Authors:  Angela Pirillo; Fabrizia Bonacina; Giuseppe Danilo Norata; Alberico Luigi Catapano
Journal:  Curr Atheroscler Rep       Date:  2018-02-14       Impact factor: 5.113

Review 5.  Mechanisms of Myocardial Damage Due to Hyperlipidemia: A Review of Recent Studies.

Authors:  Zhiqi Zhang; Hongyi Wu; Tao Wang; Yao Liu; Chun Meng
Journal:  Med Sci Monit       Date:  2022-09-16

6.  Carotid Intima-Media Thickness Progression as Surrogate Marker for Cardiovascular Risk: Meta-Analysis of 119 Clinical Trials Involving 100 667 Patients.

Authors:  Peter Willeit; Lena Tschiderer; Michael J Sweeting; Simon G Thompson; Matthias W Lorenz; Elias Allara; Kathrin Reuber; Lisa Seekircher; Lu Gao; Ximing Liao; Eva Lonn; Hertzel C Gerstein; Salim Yusuf; Frank P Brouwers; Folkert W Asselbergs; Wiek van Gilst; Sigmund A Anderssen; Diederick E Grobbee; John J P Kastelein; Frank L J Visseren; George Ntaios; Apostolos I Hatzitolios; Christos Savopoulos; Pythia T Nieuwkerk; Erik Stroes; Matthew Walters; Peter Higgins; Jesse Dawson; Paolo Gresele; Giuseppe Guglielmini; Rino Migliacci; Marat Ezhov; Maya Safarova; Tatyana Balakhonova; Eiichi Sato; Mayuko Amaha; Tsukasa Nakamura; Kostas Kapellas; Lisa M Jamieson; Michael Skilton; James A Blumenthal; Alan Hinderliter; Andrew Sherwood; Patrick J Smith; Michiel A van Agtmael; Peter Reiss; Marit G A van Vonderen; Stefan Kiechl; Gerhard Klingenschmid; Matthias Sitzer; Coen D A Stehouwer; Heiko Uthoff; Zhi-Yong Zou; Ana R Cunha; Mario F Neves; Miles D Witham; Hyun-Woong Park; Moo-Sik Lee; Jang-Ho Bae; Enrique Bernal; Kristian Wachtell; Sverre E Kjeldsen; Michael H Olsen; David Preiss; Naveed Sattar; Edith Beishuizen; Menno V Huisman; Mark A Espeland; Caroline Schmidt; Stefan Agewall; Ercan Ok; Gülay Aşçi; Eric de Groot; Muriel P C Grooteman; Peter J Blankestijn; Michiel L Bots
Journal:  Circulation       Date:  2020-06-17       Impact factor: 29.690

Review 7.  Vascular inflammation and low-density lipoproteins: is cholesterol the link? A lesson from the clinical trials.

Authors:  Alberico Luigi Catapano; Angela Pirillo; Giuseppe Danilo Norata
Journal:  Br J Pharmacol       Date:  2017-05-05       Impact factor: 8.739

8.  Targeting inflammation to reduce cardiovascular disease risk.

Authors:  Pasquale Maffia; Giuseppe Cirino
Journal:  Br J Pharmacol       Date:  2017-11       Impact factor: 8.739

Review 9.  Emerging views of statin pleiotropy and cholesterol lowering.

Authors:  Dongbo Yu; James K Liao
Journal:  Cardiovasc Res       Date:  2022-01-29       Impact factor: 10.787

10.  Effect of egg consumption on inflammatory markers: a systematic review and meta-analysis of randomized controlled clinical trials.

Authors:  Zohreh Sajadi Hezaveh; Masoumeh Khalighi Sikaroudi; Mohammadreza Vafa; Zachary Stephen Clayton; Sepideh Soltani
Journal:  J Sci Food Agric       Date:  2019-09-30       Impact factor: 4.125

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.